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91. Summary
During the reproductive years, migraine is two to three times more prevalent in women 
compared to men. This sex difference may, at least in part, be due to the cyclic 
changes in female sex hormones and a subset of female migraineurs recognizes 
menstruation as the most important trigger of attacks. In 2004, formal diagnostic 
criteria for menstrual migraine were published in the appendix of the International 
Classification of Headache Disorders 2nd edition (ICHD II). Menstrual migraine was 
defined as attacks of migraine without aura occurring on the days centering on the first 
day of the menstrual bleeding, i.e. day -2 to +3, in at least two out of three consecutive 
menstrual cycles. In the revised version from 2013 (ICHD III beta), a requirement of 
prospective headache diaries over three menstrual cycles was added in order to 
confirm the diagnosis. This was based on previous studies reporting that women tend 
to over report menstrual migraine by self-assessment. The diagnosis is still placed in 
the appendix because it is considered as insufficiently validated. Most previous studies 
on menstrual migraine are conducted in clinic populations, and no studies have 
previously used the ICHD criteria in the general population. The purpose of the
present study was to investigate prevalence and characteristics in menstrual migraine 
in the general population.
This thesis is based on four original research papers from a population-based study on 
menstrual migraine. The participants were recruited by questionnaires mailed to 5000
women aged 30-34 years from the general population and women with self-reported 
menstrual migraine were invited to a clinical interview and examination at Akershus 
University Hospital. Subsequently, the women were instructed to complete a 
headache- and menstruation diary for three consecutive menstrual cycles. 
Among 308 eligible women who self-reported migraine in at least half of their 
menstruations by questionnaire, 237 (77%) participated in the interview. The lifetime 
prevalence of menstrual migraine was 17.6% among female migraineurs and 6.1% 
10
among all women. Only one out of seven women experienced migraine exclusively in 
relation to menstruation.
The headache diary was returned by 123 (52%) women. A substantial agreement 
between menstrual migraine diagnoses given by interview versus those given by 
diaries was found (Kappa 0.62). 
The characteristics of menstrual and non-menstrual attacks of migraine without aura 
were compared among the 56 women with a prospectively confirmed diary-diagnosis 
of menstrual migraine. In these women, menstrual attacks lasted on average nearly 11 
hours longer, were significantly more often associated with severe nausea, and were on 
average treated with 1.4 more doses of symptomatic drugs than non-menstrual attacks. 
In contrast, no differences between menstrual and non-menstrual attacks were found 
among the 25 women who had migraine without aura but who did not fulfil the 
diagnostic criteria for menstrual migraine.
The clinical interview included questions about the course of migraine during use of 
current hormonal contraception. Women with a history of menstrual migraine who 
developed contraception-induced amenorrhoea were more likely to report a reduction 
in their total migraine frequency compared women with a history of menstrual 
migraine who were not amenorrhoeic. 
Conclusion: Menstrual migraine occurs in about one fifth of female migraineurs in the 
general population and in these women, menstrual attacks are associated with more 
severe symptomatology than non-menstrual attacks. The diagnosis can be made by a 
physician’s semi-structured interview and diaries should only be required in specific 
cases. Hormonal contraception that induces amenorrhoea might be beneficial in 
women with menstrual migraine.
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3. Introduction
3.1 Migraine
Headache is the most prevalent neurological symptom and is experienced by over 90% 
of the general population at some point in life [1, 2]. More than 300 different types of 
headaches are described in the worldwide used classification system of headache 
disorders; The International Classification of Headache Disorders (ICHD). The ICHD 
divides headaches into primary and secondary forms [3]. The primary headaches are 
disorders in their own right, whereas the secondary forms are typically attributed to 
another disorder, injury or to a substance and/or its withdrawal. The two most common 
presentations of primary headaches are tension-type headache and migraine with a 
worldwide one-year prevalence of 42% and 11%, respectively [4].
Migraine is divided into two major subtypes; migraine with and without aura [3]. The 
most common type, migraine without aura (MO), is characterized by recurrent attacks 
of unilateral throbbing headache of moderate to severe intensity, associated with 
nausea, vomiting, photo-, and/or phonophobia. This type of migraine is the main focus 
in this thesis and will be detailed later. Migraine with aura (MA) affects up to one-
third of all migraineurs and is primarily characterized by the transient (5-60 minutes 
duration) focal neurological symptoms (i.e. visual, sensory, speech, motor or 
brainstem symptoms) that precede or accompany the headache [5, 6]. MA is divided 
into several subtypes according to the neurological symptoms, type of headache 
(migrainous or non-migrainous) and whether headache is present or not [3].
Although migraine is a benign disorder, it often heavily affects work and social 
functioning and reduces the overall quality of life [2, 7]. According to the Global 
Burden of Disease study from 2010, migraine is the third most prevalent disorder 
worldwide and the seventh-highest specific cause of years lived with disability [8].
Migraine is also the most costly neurological disorder in the European community, 
costing more than 27 billion Euros per year [9].
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The prevalence of migraine is similar among sexes until puberty [10]. During the 
reproductive years, it is predominantly a female disorder with a male to female 
prevalence ratio 1:2-3 [4, 11]. The prevalence of migraine in women peaks during the 
third and forth decade followed by a gradual decline, particularly following the 
menopause (Figure 1). Similar figures are observed for men, but the rise and decline 
are more gradual. 
The global lifetime prevalence of migraine is 22% in women and 10% in men. These
figures vary across the continents and are highest in Northern America and Europe, 
while they are lower in Asia and Africa [4, 12]. In Europe, the lifetime prevalence is 
16-33% among women and 6-22% in men [13]. Figures from USA indicate that 43% 
of all women and 18% of men will experience migraine at some time during their 
lifetime, most before age of 35 years [14]. In addition to the higher prevalence, most 
studies support the finding that women experience a greater symptomatology and 
migraine related disability than men [15-17].
Figure 1. Last-year prevalence of migraine by sex and age. Reprinted with 
permission from [13].
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The exact mechanism for these sex differences is not fully understood, but female 
reproductive hormones are considered to play a significant role. The ovarian hormones 
estrogen and progesterone exert effects on various neurotransmitter systems which are 
thought to be involved in the pathophysiology of migraine; the serotonergic, 
noradrenergic, glutamatergic, GABAergic and opioidergic systems [18]. The activity 
of these systems varies with the levels of ovarian hormones [18, 19]. 
3.2 The menstrual cycle
The menstrual cycle represents a complex neuroendocrinologic event involving the 
hypothalamus, the pituitary gland, and the ovaries [20]. It can generally be divided into 
three main phases; the follicular phase, ovulation, and the luteal phase (Figure 2).
The follicular phase starts with the first day of menstruation and lasts until ovulation.
During this phase, gonadotropin-releasing hormone (GnRH) from the hypothalamus 
stimulates the pituitary gland to secrete follicle-stimulating hormone (FSH), which in 
turn stimulates the development of several follicles in the ovaries. 
Figure 2 Endocrinology of the female reproductive cycle.
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One of these follicles becomes the dominant and ultimately ovulatory follicle during 
that cycle, while the others regress. The developing follicles produce estrogens which 
inhibit further FSH-release from the pituitary gland (negative feed back) and stimulate 
the release of luteinizing hormone (LH). At the time of ovulation, the mature follicle 
ruptures and releases the mature ovum as a response to a surge of LH. During the 
luteal phase, the follicle, now called corpus luteum secretes progesterone and a second 
rise of estrogen, which prepares the endometrium for fertilization. The high 
concentrations of these hormones inhibit further secretion of FSH and LH from the 
pituitary gland. If the ovum is not fertilized, corpus luteum rapidly degenerates 9-11 
days after ovulation and the concentrations of estrogen and progesterone fall. The 
withdrawal of progesterone results in the menstrual bleeding.
The average duration of a menstrual cycle is 28 days, i.e. the period from the first day 
of one menstrual bleed to the first day of the next. Variations in menstrual cycle 
lengths are primarily due to changes in the follicular phase, while the luteal phase 
remains relatively constant (about 14 days). There is little cycle variability among 
women between the ages of 20 and 40 years. In comparison, significantly more 
variability is observed during the first 5-7 years after menarche and for the last 10 
years before cessation of menses, which occurs at an average of age 51years [21, 22].
3.3 Menstrual migraine
During the normal menstrual cycle, the activity of the neurotransmitter systems which 
are thought to be involved in the migraine pathophysiology varies. Concomitant with 
the decline of estrogen and progesterone levels in the late luteal phase, inhibitory 
systems are at their nadir [18]. Throughout the reproductive years, menstruation is one 
of the most significant events related to the occurrence of migraine attacks [23, 24].
Prospective diary studies of female migraineurs consistently report a significant 
increased risk of MO, but not MA, during the days directly preceding and following 
the first day of menstruation, i.e. day -2 to +3 of the menstrual cycle (Figure 3) [25-
28].
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Although many women report an association between ovulation and migraine, no 
increased risk around the expected time of ovulation has been found [25-28]. Migraine 
attacks occurring at menstruation are reported to be more painful, longer lasting, and 
more disabling than attacks at other times of the cycle [28-31], but this is not 
consistent across all studies [25, 32].
Figure 3. Incidence of migraine, urinary estrone-3-glucuronide (E1G) and 
pregnanediol-3-glucuronide (PdG) levels on each day of the menstrual 
cycle in 120 cycles from 38 women. Reprinted from with permission from 
[28].
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3.3.1 The diagnostic criteria for menstrual migraine
The above described observations contributed to the development of diagnostic criteria 
for pure menstrual migraine and menstrually-related migraine presented in Table 1 [3].
The main features of the criteria are i) the MO diagnosis, ii) the timing of the attacks, 
and iii) the frequency of attacks related to menstruation.
Women with pure menstrual migraine have MO attacks occurring exclusively during 
the specific five-day window, while women with menstrually-related have additional 
attacks outside the perimenstrual window. The requirement of occurrence in two out of 
three menstruations was chosen in order to ensure association between migraine and 
menstruation. Henceforth, the collective term menstrual migraine (MM) is used to 
cover both subtypes.
The criteria were first published in 2004 in the appendix of the second edition of the 
ICHD (ICHD II) and were primarily considered as research criteria that needed further 
validation [33]. In 2013, the revised beta version of the classification was published, 
the ICHD III beta [3]. The diagnostic criteria for MM remained in the appendix and 
were unchanged from those presented in ICHD II with one exception; an additional 
requirement of prospective headache diaries during three consecutive menstrual cycles 
in order to confirm the diagnosis. This was based on a combination of clinical 
experience and studies indicating that women tend to over report MM by self-
assessment [34-36].
In the main body of ICHD III beta, another hormonal related headache is described: 
estrogen-withdrawal headache. This diagnosis is defined by headache or migraine 
developing within five days following cessation of exogenous estrogens that had been 
taken consistently for at least three weeks. The headache resolves spontaneously 
within 3 days in the absence of further estrogen [3]. Estrogen-withdrawal headache 
may well overlap with the criteria for MM, as evidenced by migraine during the 
hormone free interval of combined hormonal contraceptives [37].
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Table 1. The diagnostic criteria for migraine without aura, pure menstrual 
migraine and menstrually-related migraine from the International Classification of 
Headache Disorders 3 beta version (ICHD III beta version)*
1.1 Migraine without aura (MO)
A. At least five attacks fulfilling criteria B-D
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
C. Headache has at least two of the following four characteristics:
1. unilateral location
2. pulsating quality
3. moderate or severe pain intensity
4. aggravation by or causing avoidance of routine physical activity (e.g., 
walking or climbing stairs)
D. During headache at least one of the following:
1. nausea and/or vomiting
2. photophobia and phonophobia
E. Not better accounted for by another ICHD-3 diagnosis
A1.1.1 Pure menstrual migraine without aura 
A. Attacks, in a menstruating woman 1, fulfilling criteria for 
1.1 Migraine without aura
B. Attacks occur exclusively on day 1±2  (i.e.GD\VíWR2 of menstruation 
in at least 2 out of 3 menstrual cycle and at no other times of the cycle
A1.1.2 Menstrually related migraine without aura
A. Attacks, in a menstruating woman, fulfilling criteria for 
1.1 Migraine without aura
B. Attacks occur on day 1±2 (i.e.GD\VíWRRIPHQVWUXDWLRQLQDWOHDVW
2 out of 3 menstrual cycles and additionally at other times of the cycle.
Notes: 
1 For the purposes of ICHD-3 beta, menstruation is considered to be endometrial 
bleeding resulting from either the normal menstrual cycle or from the withdrawal of 
exogenous progestogens, as in the use of combined oral contraceptives or cyclical 
hormone replacement therapy. 
2 The first day of menstruation is day 1 and the preceding day is day -1; there is no day 0.
*The diagnostic criteria for MO are the same in the ICHD II. The diagnostic criteria for pure and 
menstrually related migraine are also the same, except the requirement of prospective records.
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3.3.2 Pathophysiology of menstrual migraine
Even though formal diagnostic criteria for MM have only existed for 10 years, the 
association between menstruation and migraine is not a new discovery. In his book De 
Hemicrania Menstrua from 1660, Johannes van der Linden described a particular 
severe case of one-sided headache associated with nausea and vomiting which 
occurred monthly in proximity to the menstrual flow [38]. The patient was the 
Marchioness of Brandenburg.
As described above, the premenstrual phase is characterized by declining plasma 
levels of estrogens and progesterone (Figure 2). From 1970 to 1975 the role of ovarian 
hormones in the pathophysiology of MM was systematically explored in a small 
sample of women by the Australian neurologist Somerville [39-42]. He observed that 
depot-estradiol administered a few days before menstruation prevented menstrual 
migraine attacks, despite occurrence of menstrual bleeding. In contrast, progestins 
given during the same time interval only delayed menstruation, while migraine still 
occurred at time of the expected menstrual flow, as estrogen levels declined. These 
observations resulted in the estrogen-withdrawal hypothesis, which recognizes the 
decline in plasma estrogen levels as the trigger of menstrual migraine attacks. 
However, estrogen levels declines at two points in the menstrual cycle; post-ovulatory 
and premenstrual, but only the premenstrual decline is associated with migraine. 
Somerville hypothesized that several days of exposure to high levels of estrogens were 
necessary before withdrawal of estrogen could result in migraine [43].
The estrogen-withdrawal theory was further supported by a study demonstrating that 
the incidence of MO was inversely associated with urinary estrogen levels across the 
menstrual cycle (Figure 3) [28]. In addition, estrogen supplements during the 
perimenstrual period have been effective in preventing menstrual attacks [44-46], but 
post-dosing migraine may occur after ending the treatment [46, 47].
Increased occurrence of MO is also associated with other situations of estrogen-
withdrawal, such as the days directly postpartum [48-50] and during the hormone-free 
interval in women using combined hormonal contraception [37, 51]. This may 
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additionally indicate that ovulation is not a necessary precursor of attacks to be 
provoked by estrogen-withdrawal, and that estrogen-withdrawal can result in MO 
without concomitant menstrual bleeding. Situations with stable levels of estrogens 
such as during pregnancy or after menopause are associated with improvement of MO 
[52-54]. In turn, high-estrogen states are associated with increased risk or new onset of 
MA [55]. This typically occurs during pregnancy when estrogen levels are 30-40 times 
higher than the peak during the natural menstrual cycle [56, 57] or in women starting 
combined hormonal contraception [31, 58] or estrogen replacement therapy [59]. 
Resolution of MA often occurs following a return to lower-estrogen states. One 
proposed pathophysiological mechanism is that the high levels of estrogens enhance 
susceptibility to MA by increasing cortical excitability [19].
Besides the effects of ovarian steroids on neurotransmitter systems, other processes 
relevant to the pathophysiology of MM may occur at the same time as estrogen-
withdrawal, e.g. endometrial release of prostaglandins [60, 61]. There is a threefold 
increase in prostaglandin levels in the endometrium from the late follicular to the 
luteal phase with a further increase directly before menstruation [62]. Maximum entry 
of prostaglandins and its metabolites into the systemic circulation occurs during the 
first 48 hours of menstruation. Migraine patients report delayed migraine-like attacks 
after injection of prostaglandin E2 and prostaglandin I2 [63, 64] and systemic release of 
prostaglandins at the start of menstruation has been proposed as a trigger of MM [65, 
66]. In contrast to estrogen-withdrawal migraine which can occur in the absence of 
menstrual bleeding, prostaglandin levels are linked to menstruation. An association 
between MM and dysmenorrhoea, a condition with symptoms mediated through 
endometrial prostaglandin-release, has been suggested [67] and non-steroidal anti-
inflammatory drugs (NSAIDs) have been effective both as perimenstrual prophylaxis 
and in the acute treatment of MM attacks [68, 69].
The fact that menstruation is only associated with MO in a subset of female 
migraineurs, might indicate that additional genetic or environmental factors play a 
role. To date, few studies specifically address possible genetic variations in menstrual 
migraineurs. In a population of 437 women, variants in two specific genes -Tumor 
22
Necrosis Factor (TNF) and Synaptic Nuclei Expressed (SYNE1), were significantly 
associated with MM [70]. Other studies have shown a positive correlation between 
polymorphisms in estrogen and progesterone receptor genes with migraine [71, 72].
In the same way that migraine fluctuates in frequency and severity over time, the 
association with menstruation is similarly inconsistent [66]. Few women report a 
constant association between migraine and menstruation from menarche to 
menopause. This may indicate that the occurrence of MM is determined by more than 
one factor.
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4. Aims of the thesis
The overall aim of this thesis was to increase the knowledge about MM in the general 
population. The more specific aims of the individual papers are listed below;
Paper I: To estimate the lifetime prevalence of migraine and MM in women from the 
general population. Secondly to describe other types of migraine related to 
menstruation.
Paper II: To assess the consistency between MM- diagnoses made by a semi-
structured clinical interview compared with diagnoses from prospective headache- and
menstruation diaries.
Paper III: To compare the clinical characteristics of menstrual and non-menstrual 
attacks of MO in women with and without a prospectively diary-confirmed diagnosis 
of MM. 
Paper IV: To evaluate the consequences of contraceptive-induced amenorrhoea on 
migraine frequency, attack duration and pain intensity in women with a history of 
MM. 
24
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5. Material and methods
This population-based observational study includes a cohort of women recruited from 
a cross-sectional study. The data presented were collected over three stages; (1) initial 
screening questionnaire in 2005, (2) clinical interviews and examinations in 
2011/2012, and (3) three month prospective headache- and menstruation diaries 
directly following the interviews.
5.1 Population and screening questionnaires
In January 2005, a random age- and gender stratified sample of 15 000 women and 15 
000 men, aged 30-44 years, residing in the eastern municipalities of Akershus County, 
was drawn from the Central Population Registry by Statistics Norway. The sampling 
area consists of rural and urban areas and was chosen due to its proximity to Akershus 
University Hospital. The total population of the sampling area was 338 670, 
representing 7.4% of the Norwegian population. The sample represented 36.6% of 
those aged 30-44 years in the eastern municipalities of Akershus County and 2.9% of 
this age group in Norway. Data from statistics Norway show that the sampling area 
was representative of the total Norwegian population concerning age and marital 
status. Regarding employment, trade, hotel/restaurant, and transport sector workers 
were overrepresented, while industry, oil/gas and financial services were 
underrepresented [73].
A short screening questionnaire (appendix 1) was mailed to all people in the sample 
with the purpose to identify subjects for two separate studies; “The Akershus study on 
chronic headache” and the present study. While the first study included responders 
reporting chronic headache, the present study excluded subjects with chronic headache 
[73, 74].
Due to lack of resources, the present study was delayed by six years. Because of this 
delay, we chose to focus on the youngest group of women who were most likely to 
have regular menstrual cycles, i.e. the 5000 women aged 30-34 years in 2005. This 
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group constituted 38.6% of all women aged 30-34 years in the sampling area, and 3.0 
% of all Norwegian women in this age group [75].
The questionnaire included two questions about migraine and its relation to 
menstruation (Question 5 and 6, appendix 1). Women with self-reported migraine in at 
OHDVW RQH RXW RI WZR PHQVWUXDWLRQV ZHUH LQFOXGHG ZKLOH WKRVH UHSRUWLQJ 
headache days during the preceding year were excluded. The included women were 
invited to a clinical interview and examination at Akershus University Hospital in 
2011/2012. The invitation letter stated, apart from ensuring confidentiality, that the 
objective was to study menstrual migraine. One week after mailing of the invitation 
letter, the women were contacted by telephone in order to make an appointment for a 
clinical interview. Up to five calls on different days and times of the days were made, 
if necessary. 
5.2 Clinical interviews
The interviews took place at the Research Centre, Akershus University Hospital from 
September 2011 through May 2012. Women who were not able to come to the clinic 
were offered a telephone interview. The interview was based on predefined questions 
and may be termed semi-structured as the interviewer (KGV) was allowed to reword 
questions in order to improve communication. 
Classification of headaches
Two versions of the ICHD were available during the period of this work; ICHD II and 
III beta version. The criteria for MO and MM are the same in both versions (except the 
requirement for diaries), while the sub classification of MA is slightly different. The
headaches were classified according to the ICHD II by interview [33]. Pure menstrual 
migraine (A 1.1.1) and menstrually-related migraine (A 1.1.2) were classified 
according to the appendix criteria of the ICHD II [33]. If a woman experienced more 
than one type of headache, each separate form was diagnosed. 
An extended group of menstrual migraine was additionally defined in order to explore 
the boundaries of the diagnostic criteria and obtain information about other types of 
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migraine occurring in at least one out of two menstruations. This group, named all 
MM, included;
1. MM according to the ICHD-criteria: ICHD-MM
2. Probable MM, including;
a. Menstrual MA, because the migraine was MA instead of MO
b. Probable menstrual MO/MA, because
o the migraine diagnosis was probable MO/MA, or 
o the frequency of migraine related to menstruation was less than two 
out of three, but at least one out of two  menstruations, or
o the onset of MO or MA was day +4 of the cycle.
The second part of the interview encompassed questions about menstruation and 
menstrual symptoms, contraception, symptomatic and prophylactic treatment. The 
questions about contraception included type of current contraception, duration of use 
and whether amenorrhoea had arisen after initiating the method. Specific questions 
about the course of migraine in relation to current contraceptive method were included 
(appendix 2). Amenorrhoea was defined as the absence of menses for at least three 
months in women with previously normal menstruation [76, 77].
The interviews lasted 30-45 minutes and were followed by a general and neurological 
examination as recommended by the ICHD II. By the end of the interview, each 
participant was asked to complete an electronic self-administered questionnaire 
including demographic data. Women who were interviewed by telephone received this 
questionnaire by mail/email after the interview and underwent no clinical examination.
5.3 Prospective headache- and menstruation diaries
All women, irrespective of headache diagnoses, were instructed to complete a 
headache- and menstruation paper-pencil diary for three consecutive menstrual cycles 
directly following the interview. Women, who reported amenorrhoea at time of 
interview, were asked to complete the diary for three months. Each question in the 
diary was thoroughly explained to the participants. The headache diary included 
questions necessary for the distinction between MO, MA, and tension-type headache
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(appendix 3). It additionally collected information about menstruation, sick leave, and 
symptomatic treatment. 
When a headache occurred, the women were asked to record: time of onset and end of
headache, any aura symptoms, pain quality and location, severity on Numeric Rating 
Scale 0-10 (NRS; 0=no pain, 10= most severe pain), aggravation by routine physical 
activity, medical treatment and sick leave. The associated symptoms (i.e. nausea, 
photo- and phonophobia) were graded 0-3; 0=no symptoms, 1=mild, 2=moderate and 
3=severe. 
The women were allowed to take their usual medication including migraine 
prophylaxis and hormonal contraception. The diaries were returned by mail in a pre-
addressed envelope to the Research Centre. If a diary was not returned after three 
months, a single reminder was issued. 
Data entry and analyses of the diaries
The diaries were reviewed by two investigators (KGV and MBR) and all data were 
entered into the database by one person (KGV). The diaries did not cover information 
about interview-diagnoses or names of the women. In order to merge diary-data with 
the interview-data, a five-digit identification number was placed on the front page of 
each diary. In cases with missing data concerning the exact timing of menstruation, the 
subjects were contacted by telephone to elaborate the information.
When a migraine attack lasted more than one day, it was considered as a single 
multiday attack, unless a pain-free interval RIKRXUVVHSDUDWHGWKHKHDGDFKHV7KLV
definition was used since most of the attacks were treated with symptomatic drugs, and 
because migraine occurring within 48 hours is considered as a relapse in randomized 
controlled drug trials [78]. When an attack fulfilled all but one ICHD-criterion for 
MO, the attack was classified as MO if symptomatic treatment was used. Otherwise, it 
was classified as probable MO. Since some women reported visual disturbances ahead 
of their migraine attacks, not necessarily representing a migraine aura, only women 
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diagnosed with MA by interview were allowed to have their attacks classified as MA 
by diary. 
A diagnosis of ICHD-MM required at least two attacks of MO with onset on day 1±2 
of the menstrual cycle during three consecutive menstrual cycles. If an attack started 
outside the defined period (day 1±2), it was considered as a non-menstrual attack. 
Menstruation was defined as two or more consecutive days of uterine bleeding. In the 
analyses, diaries from women with oligoamenorrhoea, i.e. d1 menstruation recorded 
during three months, were excluded. In the comparison between menstrual and non-
menstrual attacks, only women who recorded attacks of MO during the diary-period 
were included. In order to compare the same headache types inside/outside 
menstruation, only MO-attacks were included, while attacks of MA and tension-type 
headache were excluded.
5.4 Statistics
The data were analysed using the Statistical Package of Social Science (SPSS) 
versions 20 and 22. 
5.4.1 Paper I
The crude and adjusted lifetime prevalence of migraine and menstrual migraine is 
presented with 95% confidence interval (CI). Since information from screening-
negative women was lacking, the number of women with self-reported migraine was 
adjusted using figures from two Danish studies, adjusting for false positive and false 
negative responses. The Danish studies validated the same question (“Have you ever 
had migraine?”) as we used to classify migraine in our questionnaires. In the first 
study, “true positive” migraineurs were 550 out of 590 people with self-reported 
migraine by questionnaire [79]. This study included a high number of subjects with 
self-reported migraine and few subjects without self-reported migraine. In the second 
study, “false negative” migraineurs were 24 out of 581 without self-reported migraine 
by questionnaire [80]. This study included few subjects with self-reported migraine 
and many without self-reported migraine.
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In the prevalence of menstrual migraine, adjustments were made for women who were 
screening-positive, but did not participate in the interview.
5.4.2 Paper II
Demographic data and comparisons of women with and without ICHD-MM were 
compared with Chi2-test for categorical variables and independent samples test for 
continuous variables. Estimations were two-sided and a p-value <0.05 was considered 
significant. 
The interview-diagnoses of ICHD-MM were compared against the diagnoses made 
according to the “gold standard”: the diary. The sensitivity, specificity and predictive 
values for the interview-diagnoses of ICHD-MM were assessed. Kappa measure of 
agreement was used to assess the consistency between the two different diagnostic 
methods, i.e. interview vs. diary. Some of the agreement may happen by chance and 
the Kappa measure of agreement corrects for this. Kappa has a maximum value of 1.00 
when agreement is perfect while a value of 0 indicates no agreement better than 
chance. Negative values indicate agreement less than predicted by chance alone. 
Values ranging from 0.41-0.60 may be considered as moderate, 0.61-0.80 as 
substantial and above 0.80 as almost perfect [81].
5.4.3 Paper III
Continuous demographic and clinical characteristics were presented as means and 
standard deviations (SDs), while frequencies and percentages were used to describe 
dichotomous characteristics. Independent samples test and Fischer’s exact test were
used to compare the characteristics between women with and without ICHD-MM.
Three continuous (pain score, duration and number of doses), three graded categorical 
(nausea, photo-and phonophobia) and two dichotomous (treatment and sick leave) 
parameters were analysed for each migraine attack, resulting in repeated 
measurements for each woman. Adjustments due to intra-correlation were made. 
Differences in menstrual and non-menstrual migraine attacks were assessed by a 
regression model for repeated measurements adjusting for intra-individual 
correlations; linear for continuous, ordinal for categorical and logistic for dichotomous 
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parameters. Intra-class correlation coefficient (ICC) was calculated to assess the 
proportion of variance occurring within-women. The regression models contained 
fixed effect for variables, categorizing the attacks into menstrual and non-menstrual 
attacks in women with and without a diagnosis of MM, with non-menstrual attacks in 
women with a diagnosis of MM as the reference category. A random effect for 
intercept, accounting for within-woman variability, was included in the model. 
The results are presented as coefficients or as odds ratios (ORs) with 99% confidence 
intervals (CIs) for categorical and ordinal data. The coefficient from a linear model 
(i.e. continuous data) represents the estimated average difference between the 
reference and three other categories (i.e. menstrual and non-menstrual attacks in 
women without MM and menstrual attacks in women with MM). Ordinal and logistic 
regression models were used to estimate the odds for presence of a specific symptom 
in a certain category with respect to the reference category. The ratio of the 
JHQHUDOL]HGȤ2 statistic and its degrees of freedom was nearly one in the logistic models 
indicating no overdispersion in the data. Baseline factors differing between the groups 
were included into the models with significant associations one at a time to test if the 
associations were modified. In addition, the models were adjusted for progestin-only 
and combined hormonal contraception. None of the associations were affected by 
these adjustments.A significance level of 0.01 was chosen to partially address for 
multiplicity.
5.4.4 Paper IV
A Fisher’s exact test with mid-p corrections  was used to compare categorical data 
from women with and without amenorrhoea; the use of mid-p corrections are 
appropriate under various conditions, and always when the groups compared are of 
(roughly) the same size [82, 83]. Differences regarding self-reported changes of MO 
between the two groups (women with and without amenorrhoea) were presented as 
Odds Ratio (OR) with 95% confidence interval. Estimations of significance were two-
sided p-values and significance level set to 0.05. 
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5.5 Ethics
The study was approved by the Regional Committee for Medical Research Ethics and 
the Data Protection Authorities. All participants who were invited to the clinical 
interview had given consent to further contact by adding their phone number to the 
screening questionnaire. The participants received written and verbal information 
about the project and inclusion was based on informed consent. The information letter 
stated the participant’s right to withdraw from the study at any time without giving any 
reason. All collected data were anonymized and secured on a research server at 
Akershus University Hospital. No reimbursement for participation or completing 
diaries was given.
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6. Results
6.1 Screening questionnaire, interviews and diaries
Figure 4 is a flow chart of the study. The response rate of the screening questionnaire 
was 73.2% (3514/4802). A total of 360 women met the inclusion criteria and were 
invited to participate in the clinical interview; 52 were not eligible. The participation 
rate of the clinical interview was 76.9% (237/308) since 71 women declined to 
participate due to lack of time, no interest, or acute illness. The majority were 
interviewed face-to-face, 63.3% (150/237). There were no significant differences 
between participants and non-participants in their responses to the screening questions 
(Table 2).
The self-administered questionnaire was completed by all women interviewed face-to-
face, and by 59% (51/87) of the women who were interviewed by telephone. 
Table 2. Questionnaire responses among participants and non-participants
Participants 
n=237
n (%)
Non-participants 
n=1231
n (%)
p-value
Do you have migraine in relation to
your menstruation? Yes 226 (95.4%) 119 (96.7%) 0.40
How often do you have migraine in 
relation to your menstruation;
x Every time 85 (35.9) 41 (33.3)
0.73x 2 out of 3 menstruations 88 (37.1) 44 (35.8)x 1 out of 2 menstruations 64 (27.0) 38 (30.9)
1Women who fulfilled the inclusion criteria, but were non-eligible or declined participation
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Figure 4. Flow chart of the study
Sample
n=5 000
Study population
n=4 802
Address error n=178
Emigrated n=15
Handicap n=5
Returned questionnaire
n=3 514 (73%)
No response
n=1 288 (27%)
Fulfilled inclusion 
criteria
n=360
Did not fulfill inclusion 
criteria 
n = 3154
Eligible
n=308
Not eligible
n=52
Participants
n=237
ICHD-MM
n=56
Analyzed diaries
n=85
Returned diary
n=123
Excluded from analyses
n=38
Did not return diary
n=114
Declined interview
n=71
No ICHD-MM
n=29
Pure menstrual migraine
n=8
Menstrually-related
migraine n=48
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Among the 237 participants, 224 (94.5%) were diagnosed with migraine. Table 3
shows clinical and demographic characteristics of the participants. Data from Statistics 
Norway show that the participants were representative of the age-and gender matched 
Norwegian population regarding employment rate and marital status. Concerning 
profession, office jobs were overrepresented while academic professions and sales-
and service were underrepresented [84].
There were no differences in the proportions of ICHD-MM diagnoses made face-to-
face versus by telephone (59% vs. 61%, p=0.73), or from the first to the second half of 
the interview period (56% vs. 63%, p=0.34). Neurological examination did not 
uncover previously unknown neurological deficits in any of the participants.
The headache and menstruation diary was returned by 123 of the 237 participants 
(52%). There were no differences between women who returned the diary compared to 
those who did not concerning migraine diagnoses, migraine frequency or demographic 
variables [85]. However, women interviewed face-to-face were significantly more 
likely to return the diary compared to women who were interviewed by telephone 
(61.3% vs. 35.6%, p<0.001). 
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Table 3. Clinical and demographic characteristics of the participants (N=237)
Clinical characteristics n %
Migraine diagnosis1 224 94.5
Migraine without aura (MO) alone 158 70.5
Migraine with aura (MA) alone 20 8.9
Migraine with and without aura (MO and MA) 46 20.5
Menstrual migraine without aura (ICHD-MM) 141 62.9
Probable menstrual migraine (probable MM) 35 15.6
Migraine prophylaxis 1 14 6.3
Hormonal contraception2 80 33.8
Combined hormonal contraception 19 23.8
Progestin-only contraception 61 76.3
Demographic characteristics n %
Married/living with a partner3 164 81.6
Have children 210 88.6
Employd3 170 84.6
+LJKHUHGXFDWLRQ\HDUVFROOHJHXQLYHUVLW\3 108 53.7
Profession4
Office and  secretarial job 47 25.4
College career, health or education, engineering 35 18.9
Academic profession 33 17.8
Sales- and service 23 12.4
Management profession 11 5.9
Craftsman, fisher, farmer 8 4.3
Other 28 15.1
1Subtypes of migraine and migraine prophylaxis are presented as percentages of all 
migraineurs. 2 Subtypes of hormonal contraception is presented as percentages of all 
women using contraception. 3 36 missing values. 4 52 missing values.
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6.2 Prevalence of migraine and menstrual migraine (paper I)
Of the 3514 women who returned the questionnaire, 1215 gave a positive response to 
the question “Have you ever had migraine?” while 2299 answered “no”. The adjusted 
number of women with migraine was 1228, i.e. (1215x (550/590)) + (2299x (24/581)). 
The crude lifetime prevalence of self-reported migraine was 34.6% (1215/3514) in the 
population and the adjusted prevalence was 34.9% (1228/3514).
The crude and adjusted lifetime prevalence figures of the different types of migraine 
related to menstruation are presented in Table 4. Menstrually-related migraine was 6.5 
times more common than pure menstrual migraine among the women with ICHD-MM
(19 versus 122 women). An active ICHD-MM, i.e. MM occurring during the 
preceding year, was reported by 65.2% (92/141). Women with probable menstrual MO 
did not fulfil the required frequency (n=6), timing of attacks (n=4) or the definite MO-
diagnosis (n=3). The women with probable menstrual MA did not fulfil attack
frequency (n=5) or timing of attacks (n=3).
Table 4. Lifetime prevalence of menstrual migraine among all women and female 
migraineurs 
Among all women
(N=3514)
Among migraineurs 
(N=1215)
n
Crude
% (95% CI)
Adjusted1
% (95% CI)
Crude %
(95% CI)
Adjusted1 %
(95% CI)
ICHD-MM 141 4.0 (3.4-4.7) 6.1 (5.4-6.9) 11.6 (9.9-13.5) 17.6 (15.6-19.9)
Probable MM
Menstrual MA 14 0.4 (0.2-0.7) 0.6 (0.4-0.9) 1.2 (0.7-1.9) 1.7 (1.1-2.6)
Probable menstrual MO 13 0.4 (0.2-0.6) 0.6 (0.4-0.9) 1.1 (0.6-1.8) 1.1 (0.6-1.8)
Probable menstrual MA 8 0.2 (0.1-0.5) 0.3 (0.2-0.6) 0.7 (0.3-1.3) 1.0 (0.6-1.7)
All MM 176 5.0 (4.3-5.8) 7.6 (6.8-8.5) 14.5 (12.6-16.6) 22.0 (19.7-24.4)
1 Example of calculation of adjusted prevalence of ICHD-MM among all women: (((141/237) x123) + 141)/3514 
=0.061. The number of women with ICHD-MM (141) divided by all participants (237), multiplied by the number of 
non-participants (123), gives the assumed number of women with ICHD-MM among non-participants (73), adding 
the 141 women with ICHD-MM among participants, gives the estimated number of affected women in the study 
population (141+73=214). Divided into all responders and multiplied by 100, gives an adjusted prevalence of 6.1%.
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6.3 A clinical interview versus prospective headache diaries (paper II)
Of the 123 returned diaries, 38 were excluded due to oligo-/amenorrhoea (n=36) or 
incompleteness (n=2). 
Among the 85 women whose diaries were analysed, 51 were diagnosed with ICHD-
MM by interview, but 56 were prospectively diagnosed with ICHD-MM by diary. The 
sensitivity, specificity, and predictive values of the ICHD-MM diagnosis given by 
interview are presented in Table 5. The observed agreement rate was 82% and the 
chance-corrected agreement rate, Kappa, was 0.62 (95% CI 0.45-0.79).
Among the 10 negatively misclassified women, six were diagnosed with probable
menstrual migraine by interview. In the five women positively misclassified by 
LQWHUYLHZWZRKDG02DWWDFNVRFFXUULQJLQUHODWLRQWRWKHLUPHQVWUXDOSHULRGV
but the attacks started earlier than required (day -5 and -4). 
When the criteria were expanded to additionally include the women with probable 
MM (n=6; four menstrual MA and two probable menstrual MO), the Kappa value was 
slightly higher; 0.64 (95% CI 0.47-0.83) with equal positive and negative 
misclassification. 
Table 5. Sensitivity, specificity, and predictive values of the clinical diagnosis 
of menstrual migraine without aura (ICHD-MM)
Diary diagnosis
MM No MM Total
Interview
diagnosis
MM 46 5 51 PPV=46/51=90%
No MM 10 24 34 NPV=24/34=71%
Total 56 29 85
Sensitivity=
46/56=82%
Specificity=
24/29=83%
PPV: positive predictive value. NPV: Negative predictive value
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6.4 Menstrual versus non-menstrual migraine attacks (paper III)
In the comparisons of menstrual and non-menstrual MO-attacks, an additional four 
diaries were excluded from the analyses, because only attacks classified as tension-
type headache were recorded. Thus, 81 diaries were analysed from 56 women 
prospectively diagnosed with ICHD-MM and 25 women with MO-attacks but not 
ICHD-MM. 
The 81 women recorded a total of 261 menstrual cycles over 7202 diary days. Overall, 
470 migraine attacks were recorded, of which 35 were classified as MA and thus 
excluded from the analyses. Of the 435 analysed MO- attacks, missing values occurred 
most frequently for attack duration (6.2%, n=27), phonophobia (1.4%, n=6), 
photophobia (1.5%, n=5) and nausea (0.5%, n=2). Information regarding sick leave 
and pain intensity was missing in one attack respectively. 
In women with ICHD-MM, the menstrual MO-attacks were significantly longer (on 
average 10.65 hours, 99% CI 3.17-18.12) and more frequently associated with severe 
nausea (OR 2.14, 99% CI 1.20-3.84) than non-menstrual MO-attacks. The menstrual 
attacks were treated with significantly more doses of symptomatic drugs (mean 
difference 1.37, 99% CI 0.50-2.24) and multiple agent treatment strategies (OR 2.10, 
99% CI 1.05-4.23). A non-significant trend towards more painful attacks (on average 
0.37 on an 11-point scale, 99% CI -0.08-0.81) and more occurrences of status 
migrainosus (OR 4.34, 99% CI 0.94; 20.09) was found, but there were no differences 
in sick leave.
No significant differences in characteristics or treatment between menstrual and non-
menstrual MO-attacks were found among women with MO, but no MM.
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6.5 Contraception-induced amenorrhoea (paper IV)
Among the 141 women with a history of ICHD-MM by interview, 49 were current 
users of hormonal contraception. Contraception-induced amenorrhoea was reported by 
23 women. Figure 5 gives an overview over the different types of hormonal 
contraception used by the women.
*Expected inhibition of ovulation. LNG-IUS: Levonorgestrel intrauterine system. DMPA: 
Depot medroxyprogesterone acetate.  CHC: combined hormonal contraception.
A reduction in the total MO-frequency was significantly more often reported by 
women with amenorrhoea compared to women without amenorrhoea (OR 3.5, 95% CI 
1.1; 11.4, p=0.04). No difference was found with respect to attack duration and pain 
intensity. Women with amenorrhoea were more likely to report that they were 
migraine-free during the preceding month compared to women without amenorrhoea 
(OR 16.1, 95% CI 1.8; 140.4, p=0.003). 
An additional analysis of contraceptive methods with and without expected inhibition 
of ovulation was carried out. Women using expected anovulatory methods were less 
likely to report a reduction in migraine-frequency compared to those with preserved 
ovulation (OR 0.2, 95% CI 0.1; 0.9, p=0.03). Again, no differences concerning 
duration and pain intensity were found.
Figure 5. Current users of hormonal contraception
Current users of hormonal 
contraception
N=49
Amenorrhoea, n=23
x 19 LNG-IUS
x 3 Desogestrel-only pill*
x 1 DMPA-injection*
No amenorrhoea, n=26
• 12 LNG-IUS
• 11 CHC*
• 2 Desogestrel-only pill*
• 1 progestin-only mini-pill
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7. Discussion
7.1 Methodological considerations 
This observational study includes a cohort of women recruited from a population-
based cross-sectional study. The study comprises retrospective data from 
questionnaires and interviews as well as prospectively recorded data from diaries. 
Retrospective data are associated with recall bias, and selection bias may have 
occurred along the three stages. These issues will be discussed more specifically in 
relation to each stage. 
7.1.1 Population and screening 
Women with self-reported migraine in at least one out of two menstruations were 
recruited from a large population-based sample. The large sample size and high 
response rate (73%) to the questionnaire should provide representativeness of women 
aged 30-34 years in the general population. Since the screening questionnaire only 
included questions about headache, headache sufferers may be overrepresented among 
the responders. For ethical reasons we were not allowed to contact non-responders. A 
Danish population-based study did not find difference in headache diagnoses between 
responders and non-responders [79].
The questionnaire included two questions about menstrual migraine; “Do you have 
migraine in relation to your menstruation?” and “How often do you experience 
migraine in relation to your menstruation?” A review of the questionnaires identified 
some women who had failed to respond, or gave a negative response to the first 
question, but still replied to the second question. No one answering ‘yes’ to the first 
question had missing values on the second question. In order to make a broad 
inclusion, we chose the latter as our key question for inclusion. In addition, we 
included women who reported migraine in 1/2 menstruations instead of 2/3 to further 
increase ascertainment. 
Due to our screening method, some women with MM in the original population have 
probably not been identified. We did not interview screening-negative women. No 
studies have evaluated MM diagnoses in women who report that they do not have 
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MM. However, previous studies have shown that women tend to over report MM by 
self-assessment [35, 36]. Interviews of responders with migraine who did not report 
MM may have given additional data and contributed to more precise prevalence 
estimates of MM in our study. Some women may not know that their headache was a 
migraine. However, the question: “Have you ever had migraine?” has previously been 
validated with a high chance corrected agreement rate (kappa 0.87) and it identifies 
about 80% of migraineurs [80]. Our population encompassed all women who had 
answered ‘yes’ to that question, but additionally some who had answered ‘no’ to the 
migraine question, but ‘yes’ to the menstrual migraine questions in order to make a 
broad inclusion. Women with onset of MM after screening and before interview could 
not be identified by our study design. As a consequence of this, our lifetime prevalence 
figures are only valid for women aged 30-34 years and should be considered as a 
minimum of the true prevalence for this group. 
The six years delay between screening and interview has probably increased the 
influence of recall bias and may have led to an underestimation of the prevalence 
estimates in paper I. It may also have contributed to a lower participation rate. This 
delay did probably not influence the results of paper II and III, since these papers only 
include data collected in close temporal relation from interviews and prospective 
headache diaries. Regarding paper IV, the six years delay provided an opportunity for 
a retrospective analysis of women in whom their MM had ceased due to contraception-
induced amenorrhoea. 
7.1.2 Clinical interviews 
In the absence of biological markers for migraine, the diagnosis is based on the 
subjects’ history and recall of specific symptoms. A clinician’s interview is considered 
as the gold standard in terms of diagnosing specific headache disorders, especially in 
subjects with more than one type of headache [86]. A face-to-face interview has, in 
contrast to a telephone interview, the advantage that it allows participants to be 
examined, which is recommended by the ICHD in order to rule out secondary 
headaches [3, 33]. However, a face-to-face interview is time-consuming and 
consequently expensive compared to both telephone interviews and questionnaires. 
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The invitation letter stated that the purpose was to study menstrual migraine, and 
menstrual migraineurs may be overrepresented among the participants (participation 
bias). However, participants and non-participants did not differ regarding their 
questionnaire responses concerning menstrual migraine. 
7.1.3 Prospective headache diaries
In clinical practice, patients may have difficulties recalling precisely the headache 
characteristics, especially if they have several types of headache. The episodic nature 
of the disease constitutes a bias towards the most severe or recent headache attack
[87]. Moreover, difficulties are related to the headache syndromes themselves, because 
clinical features may change from one attack to the next. In menstrual migraine both 
the timing of attacks in relation to the first day of menstruation, and the frequency 
related to menstruation, represent additional challenges. The most precise descriptions 
of migraine characteristics and the timing of migraine in relation to menstruation are 
thus likely to be obtained from prospective headache- and menstruation diaries which 
are less influenced by recall bias than a clinical interview. 
The major concern about the use of diaries is the low compliance rate, as demonstrated 
in our (52%) and previous studies [25, 26]. Recording diaries is time consuming and 
patients tend to be less compliant in maintaining them over long periods of time [88]. 
For the purpose of this study, we used a diagnostic diary with series of multiple 
questions in order to distinguish between headache types (appendix 3). The three 
months period and the rather comprehensive design of the diary might have been too 
demanding for some women, resulting in the modest compliance rate. However, since 
we wanted to categorize each attack, multiple questions were inevitable, and the ICHD 
requires a long period (i.e. three months) in order to establish the diagnosis of MM. 
Frequent reminders, a closer monitoring during the diary-period, a compensation for 
filling in the diary, and/or a re-visit after three months, could possibly have increased 
the return rate. Despite the extensive questions, only two diaries were incomplete and 
not eligible for analysis. The thorough explanation in advance may have contributed to 
this. 
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Even though the participants were aware that the objective was to study menstrual 
migraine, no differences were found between women who returned the diary and those 
who did not regarding clinical ICHD-MM diagnosis, migraine frequency, or 
amenorrhoea [85]. The only difference detected was type of interview; women who 
were interviewed face-to -face were significantly more likely to return the diary 
compared to those interviewed by telephone. This may indicate that 1) women who 
invested more time in order to come to the hospital for a face-to-face interview were 
more motivated and interested in participation and/or that 2) the personal contact with 
the interviewer increased the motivation and engagement. 
A paper-pencil diary is easy to use and a low-cost low-threshold method, but is also 
connected with the possibility of backfilling entries [88]. In turn, electronic diaries 
may be associated with technical challenges and possible selection bias [89]. During 
the past years, an increasing proportion of the Western population own a smartphone 
and a variety of headache diary applications (Apps) are available free of charge. This 
portable and fast-access method might represent a better means to achieve higher 
compliance rates. During the period when the diaries in our study were recorded, only 
60% of all Norwegians owned a smartphone, as compared to >80% today [90]. A 
disadvantage may again be selection bias towards inclusion of subjects with higher 
socioeconomic status.
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7.2 Discussion of the results 
7.2.1 Prevalence of migraine and menstrual migraine 
The lifetime prevalence of migraine and menstrual migraine were defined as the 
proportion of women who fulfilled the criteria of migraine or menstrual migraine at 
any time during their lives. This is equivalent to the lifetime risk. The lifetime 
prevalence of migraine includes both those with an active disease and those who are
into remission. Conversely, the one-year prevalence and the point prevalence are 
functions of incidence (i.e. new cases) and remission (ceased cases) during a specific 
period and are generally lower than the lifetime prevalence. The lifetime prevalence 
may be more influenced by recall bias, especially when the participants are older and 
their migraine went into remission several years ago. Another drawback is that lifetime 
prevalence does not give a clear indication of those actually having an active disease. 
Our 34.9% lifetime prevalence of migraine among women in their 30s is comparable 
to figures from the Netherlands, Germany, Canada, USA and South America [14, 91-
94], but is higher than other studies from Europe and Asia [79, 95, 96].
Prevalence of menstrual migraine
We chose to present lifetime prevalence figures of MM based on interview-diagnoses 
instead of the diary-diagnoses due to the modest compliance rate of the diaries. We 
also present prevalence figures for the total female population and for women with 
migraine, since one or both are presented in previous studies. 
A review of the literature revealed great variations in prevalence figures of MM, 
ranging from 4% to 70%. This can be explained by differences in the study 
populations, assessment, and varying definitions of MM. Figure 6 illustrates some 
factors contributing to the differences.
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Prevalence figures from at least five different populations are presented in the 
literature: all women in the general population [30, 97, 98], female migraineurs in the 
general population [5, 97-100], female migraineurs attending to headache clinics [27, 
31, 58, 101, 102] and women in an obstetrics and gynecology setting [103]. In 
addition, some present prevalence figures confined to women with MO or MA, while 
others refer to all women with migraine. 
The prevalence of MM is naturally higher among female migraineurs than among all 
women. The definition of MM requires a minimum frequency of migraine; at least two 
attacks during three months, which is above the average frequency reported by 
Figure 6. Influences on the prevalence figures of menstrual migraine
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migraineurs from the general population [104]. MM is thus more likely to occur in a 
headache clinic population, as shown in Figure 7. Two studies from the general 
population stand out, probably due to looser definitions of MM, this will be discussed 
below [98, 99].
Figure 7. Prevalence of menstrual migraine in different study populations
Our 17.6% lifetime prevalence of ICHD-MM among all female migraineurs aged 30-
34 years is slightly lower than lifetime prevalences from Swedish (21.2%) and Danish 
(24.8%) population-based studies [5, 100]. These prevalence-figures are confined to 
women with MO. A simplified adjustment assuming that 2/3 of all female migraineurs 
have MO, indicates that 26% of women with MO have ICHD-MM in our population. 
The two Scandinavian studies did also includHROGHUSRSXODWLRQVLHZRPHQ\HDUV
old. We have previously published prevalence figures based on the questionnaire 
responses from all women aged 30-44 years in our original population [97]. The 
lifetime prevalence of self-reported MM increased slightly with age, from 19.8% in 
female migraineurs aged 30-34 to 21.7% among those aged 40-44 years [97].
However, differences in study populations alone can probably not explain the 
disparities. Due to the lack of uniform criteria until 2004, different definitions of MM 
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have been used; including various definitions of the perimenstrual period and the 
required frequency of migraine related to menstruation. The perimenstrual period has 
been defined as all days occurring between day -3 until 3 days after menstruation [58],
from day -3 to +5 [99], from day -3 to +3 [105] or from day -2 to +2 [30]. Similarly, 
has the required frequency of concurrency between migraine and menstruation been 
defined as “attacks mostly occurring during menstruation”[101], “aggravation of 
migraine during menstruation”[98], attacks occurring regularly just before or after 
menstruation [102] – or a definition is lacking [30, 99]. The highest prevalence figures 
are found in studies which either define an extended perimenstrual period or in studies 
not considering the frequency of migraine related to menstruation; 57-79% [58, 98, 99, 
101].
Even though most researchers after 2004 have used the same criteria, they may have 
been differently interpreted; as the current criteria do not clearly state that the attacks 
have to start on day 1±2. If only migraine days occurring during the five perimenstrual 
days are counted, without considering time of onset of the attacks, most women with 
chronic migraine will naturally fulfil the criteria for MM. 
Previous studies have used different methods in the assessment. A subjective 
assessment by the patients themselves, rather than careful interviews or prospective 
diaries, may lead to an overestimation of MM [35, 36], but there is no consistency in 
the previous prevalences indicating that one method leads to higher figures than the 
other. This is probably explained by some of the above-mentioned issues.
Prevalence calculation is about numerators, denominators, and time. What we 
enumerate (i.e. women with MM) has differed due to different definitions of MM and 
time frame (i.e. life-time vs. one-year). The denominators differ because different 
populations have been studied. By presenting the lifetime prevalence of ICHD-MM, 
we have shown the percentage of female migraineurs who are at risk of experiencing 
menstrual migraine until age 30-34 years. Even though our study was not perfectly 
designed for prevalence estimations (due to the six years delay), no other studies have 
presented prevalence figures for MM in the general population based on the ICHD 
criteria. 
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Menstrual migraine among all women in the general population
We found a 6.1% prevalence of ICHD-MM and 7.6% prevalence of all menstrual 
migraine among all women in our population. The prevalence among all women from 
the general population has been calculated in two previous studies [30, 98] (Figure 7).
The Dutch questionnaire-based study of regularly menstruating women aged 13-55 
reported a prevalence of 3.9% [30], probably representing last-year prevalence.  If we 
consider that about two thirds (92/141) of all women with ICHD-MM in our study had 
MM during the preceding year, the Dutch results are similar to our figures.
A second paper reports on a Serbian questionnaire-study of female students aged 18-
28 years [98]. The prevalence reported was 7.6%, but the definition of MM was less 
specific; i.e. “migraine aggravated during menstruation” and might be more 
comparable to our all MM group, where we found a prevalence of 7.6%. 
Prevalence of the subtypes; pure and menstrually-related migraine
Only 19 out of 141 women with MM had pure menstrual migraine. The lower figures 
of pure menstrual migraine as compared to menstrually related migraine are consistent 
with all previous studies from clinic and the general populations, except one study 
from the obstetrics and gynecology population [103]. The prevalence of pure 
menstrual migraine varies less across studies, probably due to the more uniform 
definition restricted to include women with exclusively menstrual attacks.
The variations in prevalence figures of MM are thus mainly caused by variations in the 
proportion of women with menstrually-related migraine. This is primarily caused by 
the different definitions of menstrual migraine described above.
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Extended criteria MM –why include this group?
The diagnostic criteria for MM are placed in the appendix of the ICHD II and III beta. 
The primary purpose of the appendix is to present research criteria for novel entities 
that have not been sufficiently validated by research so far [3, 33]. In order to explore 
the boundaries of menstrual migraine, we expanded the criteria to include probable 
MM, i.e. women fulfilling all, but one ICHD appendix criteria for MM, in addition to 
probable menstrual MA (violates two criteria). One fifth of all women had probable 
MM. “Probable-diagnoses” are given for all primary headaches in the ICHD and 
people may fulfil the definite diagnoses at some time and at other times the probable 
diagnoses. In clinical management, the probable-diagnoses provide a basis for 
treatment pending later diagnostic confirmation [86]. Comparisons of our interview-
and diary- diagnoses may indicate that this could be relevant for the diagnosis of MM 
as well. 
6L[ZRPHQUHSRUWHG02LQEXWPHQVWUXDWLRQVE\LQWerview and four stated 
that their migraine attacks started regularly on day +4 of the menstrual cycle. It is well 
known that inter- and intra-individual variations in the levels of ovarian hormones 
between the menstrual cycles occur and that each menstrual cycle is not a reproducible 
hormonal event [106-108]. In certain individuals this may cause an earlier or later 
trigger (e.g. estrogen-withdrawal), leading to attacks just outside the five-day window. 
In others, the hormonal fluctuations may not exceed the threshold for triggering a 
migraine attack in each cycle. Likewise, the levels of prostaglandins in the menstrual 
fluid tend to fluctuate at different times during different cycles [62]. In clinical 
practice, these women may be treated in the same way as menstrual migraineurs but 
for the purpose of research, inclusion of such “outliers” may result in a less 
homogenous group and thus dilute results. 
Only menstrual attacks of MO are considered in the diagnosis of MM, while no 
requirement for the non-menstrual migraine type is given. Separate analyses of MO 
and MA consistently report that MO is more likely than MA to be associated with 
menstruation. The previous prevalence figures for menstrual MA among women with 
MA are 4% -37% [5, 58, 100, 101]. We found a prevalence of 1.7% of menstrual MA 
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among all migraineurs. If we assume that 1/3 of all migraineurs have MA, the 
prevalence of menstrual MA would be about 5% in women with MA in our study.
In contrast to this, a diary-study of women with frequent MA attacks found a 
significantly increased risk of MA on day +1-+3 of menstruation compared to other 
times of the cycle (OR 2.41; 95% CI 1.62-3.59) [109]. This study only described the 
timing of attacks related to menstruation but not the frequency. Menstruation was also 
reported to be a significant trigger of MA-attacks in a questionnaire study [110].
Among the 14 women diagnosed with menstrual MA by interview in our study, only 
four returned a diary. All recorded MA-attacks on day 1±2 in 2/3 menstruations in 
theiU GLDULHV ,Q  FDVHV WKHLUPHQVWUXDO DWWDFNV UHSUHVHQWHG RI DOOPLJUDLQH
attacks (unpublished data), compared to the average 47% of women with ICHD-MM, 
indicating that a chance occurrence is less likely. Until further evidence is available it 
could be worth including menstrual MA into the appendix of the ICHD in order to 
explore potential underlying pathophysiological mechanisms. In turn, it is absolutely 
necessary to analyse menstrual MO and MA separately.
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7.2.2 A clinical interview diagnosis of menstrual migraine
The diagnosis of MM differs from most other conditions in the ICHD by virtue of the 
temporal relationship with a specific event: menstruation. Besides a precise headache 
diagnosis, the attacks have to be correctly timed and occur in a specific frequency in 
relation to menstruation. Three previous clinic studies have demonstrated this 
challenge, as MM was over reported in 19%, 62%, and 89% of women by self-
assessment [34-36]. As a consequence of this, the recommendation of three months 
prospective records in the ICHD II was changed to a requirement in the ICHD III beta 
version. MM has thus its special position in the ICHD III beta as the only headache 
diagnosis requiring a diary before establishment. This has some practical implications 
since the diagnosis cannot be made during the first visit and women who are non-
compliant in recording diaries can never be diagnosed. 
In contrast to the previous studies, we found a substantial agreement between 
diagnoses of ICHD-MM made by interview versus diary (Kappa 0.62). The diagnosis 
was confirmed in 90% (46/51) of all women diagnosed with ICHD-MM by interview. 
This is in line with one previous study [111]. Unlike the previous studies, we 
additionally evaluated women without an ICHD-MM diagnosis from interview, and 
found a tendency towards under reporting.
The interviews were however imprecise in the discrimination between pure and 
menstrually related migraine. Eight women were diagnosed with pure menstrual 
migraine by interview and seven by diary; in only three cases did it represent the same 
woman. The three months period might have been too short to detect non-menstrual 
attacks in women misclassified as menstrually-related migraine by interview. 
A clinical interview, based on the ICHD-criteria, is though valid for the diagnosis of 
MM. Headache diaries should not be mandatory in order to diagnose MM, but might 
be necessary in order to distinguish between the subtypes of MM, monitor treatment 
and to exclude a chance association. 
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7.2.3 Menstrual versus non-menstrual attacks of migraine without aura
Menstrual attacks of MO were significantly longer, more often associated with severe 
nausea and required a higher number of symptomatic drugs compared to non-
menstrual MO attacks in women prospectively diagnosed with ICHD-MM. These 
findings are in line with previous studies conducted on menstrual migraineurs from 
clinic populations [28-31, 112], but have never been demonstrated in the general 
population using diaries (Table 6). Studies conducted on all female migraineurs, report 
divergent findings concerning possible differences [24, 25, 32, 113, 114]. These 
studies include all women with migraine, instead of restricting the sample to women 
with MM, and are probably likely to include women who coincidentally happened to 
experience a migraine during one of the menstrual periods studied. 
The longer duration and more resistance to acute therapy of menstrual attacks as 
compared to non-menstrual attacks are consistently reported across the previous 
studies of menstrual migraineurs [24, 29-31, 112]. The menstrual attacks in our study 
were treated with a significantly greater number of symptomatic drugs and lasted on 
average nearly 11 hours longer than non-menstrual attacks. Both findings may be 
explained by a prolonged trigger or indicate higher resistance to treatment. The 
significantly higher number of triptan doses per menstrual attack can be the result of 
lower effectiveness of the first dose or higher relapse rate. All, but one previous study 
comparing treatment efficacy between menstrual and non-menstrual attacks in women 
diagnosed with MM have been performed in selected clinic populations, where 
patients might be more resistant to treatment [115]. Our results may indicate that 
menstrual attacks are more resistant to treatment also in the general population.
Whether menstrual and non-menstrual attacks differ with respect to pain intensity and 
associated symptoms is not clearly demonstrated, as the results differ across the 
studies of menstrual migraineurs (Table 6). We did not find a significant difference in 
pain scores. These findings might have been influenced by the higher consumption of 
symptomatic drugs during the menstrual attacks. The occurrence of more severe 
nausea is in line with one of the previous studies [28], while two others reported no 
difference [29, 31]. Nausea can be related to the side-effects of the higher number of 
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symptomatic drugs or due to systemic prostaglandin-release around the first day of 
menstruation.
We were not able to detect significant differences between menstrual and non-
menstrual attacks in women who did not fulfil the diagnostic criteria for MM. Bearing 
in mind that the group of women without MM was small we cannot exclude the 
possibility that these analyses were underpowered. The lack of difference could though 
indicate that women with MM represent a subset of female migraineurs with a distinct 
“drive” of their attacks.
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7.2.4 Contraception-induced amenorrhoea 
Ever since the estrogen-withdrawal theory was launched in the 70ies, the theory has 
hardly been challenged and little attention have been directed towards other potential 
pathophysiological mechanisms, e.g. the role of the menstrual bleeding as such.
Among menstrual migraineurs in our population using hormonal contraception, 
achievement of amenorrhoea was associated with a self-reported reduction in migraine 
frequency. According to the estrogen-withdrawal hypothesis, one would expect that 
the improvement in amenorrhoeic women was caused by hormonal contraception that 
suppresses the hypothalamus-pituitary-ovary axis, consequently reducing the hormonal 
fluctuations. However, the majority of women with amenorrhoea in our study used the 
LNG-IUS (19/23), a method that mainly exerts its effects locally within the 
endometrial cavity with strong suppression of growth and induction of endometrial 
insensitivity to ovarian estradiol. Only about 15% of LNG-IUS users develop 
anovulation and the incidence is similar in women with and without amenorrhoea 
[116]. The plasma levels of estrogens and progesterone are also similar in LNG-IUS 
users with and without amenorrhoea, indicating that the absence of menstrual bleeding 
is not a predictor of ovarian function but a result of the local endometrial changes 
[117].
Reports evaluating the effect of hormonal contraception in relation to MM are limited 
and have mostly focused on prevention of estrogen withdrawal. Combined hormonal 
contraception (CHC) is usually given in a 21/7 regimen, i.e. 21 days with active 
hormones (estrogens and a progestin) followed by a seven days hormone-free interval, 
which is associated with withdrawal bleeds. Alternative dosing regimens, such as 
extended cycle with active hormones for 84-168 days followed by a 4-7 days
hormone-free interval, or continuously use of active hormones without a hormone-free 
interval, have been studied. Such dosing regimens eliminated MM in 91% of women 
with very frequent migraine and reduced headache scores in another study [118, 119].
This effect was explained through stabilization of estrogen levels in one of the studies
[118]. Another strategy, CHC with a shortened hormone-free interval of four, instead 
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of seven days, was associated with a significant reduction in attack duration and pain 
intensity –but not frequency, of menstrual migraine attacks [120]. This was explained 
by a shorter period of hypoestrogenism. Neither of the studies provides exact 
information about changes in bleeding pattern. While extended regimens of CHC are 
associated with reduction/absence of withdrawal bleeds during the period of active 
hormones, the shortened hormone free interval reduces the duration and/or quantity of 
bleeding, but not the incidence of withdrawal bleeds [121, 122]. Continuous use 
induces amenorrhoea in 80% to 100% of women [123]. The hormonal manipulations 
may thus not be the only explanation of the positive outcomes in these studies; a 
change in menstrual bleeding may also play a role. This is supported by one study 
reporting changes in bleeding patterns in menstrual migraineurs using a combined 
contraceptive pill administered with a very short hormone-free interval (two days). 
This administration resulted in a significant reduction in bleeding days and significant 
reduction in the frequency, intensity and duration of migraine attacks in women with 
menstrually-related migraine [124].
If the bleeding as such plays a role, systemic prostaglandin-release during the first 48 
hours of menstruation may be a potential mechanism, as intravenous infusion of 
prostaglandins is known to trigger migraine attacks in subjects with migraine [62-64, 
125, 126]. It could be hypothesized that the observed benefit of contraception-induced 
amenorrhoea in women with ICHD-MM was a result of reduced prostaglandin 
synthesis and subsequently diminished release from endometrium. Since the systemic 
release of prostaglandins coincides with the falling levels of estrogens, both 
mechanisms may be responsible for triggering menstrual migraine attacks. Elimination 
of at least one of the pathways/mechanism, may lead to improvement.
Categorizing the diverse types of contraception into two groups based on the effect on 
withdrawal bleeds/menstruation may seem overly simplistic due to the different 
mechanisms of action in the diverse types. However, the aim of this retrospective 
analysis was to explore the effect of amenorrhoea per se and our study did not include 
enough cases to describe each type of contraception separately. The majority of 
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amenorrhoeic women used the LNG-IUS and no former studies have evaluated the 
effect of the LNG-IUS on menstrual migraine.
The low number of women using hormonal contraception and the retrospective design 
represent obvious limitations of these analyses. Paper IV is first and foremost meant to 
be hypothesis-generating and only future prospective studies evaluating the effect of 
amenorrhoea using different strategies to achieve amenorrhoea -with and without 
inhibition of ovulation, can provide more robust answers. 
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8. Conclusion and the future
About one fifth of all female migraineurs have migraine occurring during the 
perimenstrual period in at least 50% of their cycles and the majority of these women 
fulfil the ICHD criteria for MM. The lifetime prevalence of ICHD-MM was 17.6% 
among female migraineurs and 6.1% among all women aged 30-34 years in this
general population. A thorough clinical interview is valid for the diagnosis of MM, but 
cannot replace a diary for the diagnosis of the subtypes of MM; pure and menstrually 
related migraine. Menstrual migraine attacks are associated with more severe 
symptomatology, but only in women who fulfil the diagnostic criteria for MM.
Women with a history of ICHD-MM reported improvement of their total frequency of 
MO after initiating progestin-only contraception leading to amenorrhoea. While 
estrogen-withdrawal has been promoted as the main trigger for menstrual attacks, this 
research suggests that an alternative pathophysiology associated specifically with 
menstrual bleeding may play a role as a trigger of menstrual attacks.
8.1 The diagnostic criteria of menstrual migraine
This study raised some questions about the diagnostic criteria for MM. The wording in 
the ICHD-criteria: “... attacks occur on day 1±2 of the menstrual cycle...” opens for 
misinterpretation. MM may be diagnosed if one day in a multiday-attack occurs within 
this time period, even if the attack started earlier than day -2. The wording “…attacks 
starting on day 1±2 of the menstrual cycle...” is less ambiguous. 
The criteria allows for inclusion of women in whom the association between migraine 
and menstruation is weak, since no upper limit of non-menstrual attacks is defined. 
This contradicts the aim of the criteria: to identify women with an association between 
migraine and menstruation that is greater than by chance [127]. Inclusion of such cases 
is likely to dilute research results and additional methods for exclusion of chance 
occurrence among women who otherwise fulfil the ICHD-criteria would improve the 
diagnostic criteria. One proposed algorithm is that the number of non-menstrual 
migraine days must be no more than double the number of menstrual migraine days
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[127]. A statistical approach for association has also recently been published [128].
Calculations from this paper indicate that an observational period of three consecutive 
menstrual cycles is too short to determine whether an association is present and that a 
minimum of four perimenstrual periods are needed. This method is awaiting clinical 
validation.
As previously shown and discussed, a small subgroup of women with MA experienced 
regularly MA-attacks in relation to menstruation. Whether these women share the 
same pathophysiological mechanisms as women with ICHD-MM is unknown.
Inclusion of this group into the appendix of the ICHD III could facilitate research on 
this group.
MM affects more women than most other headache disorders recognized by the ICHD. 
Women with MM may have different pathophysiology of their menstrual attacks 
concerning the differences in symptomatology and greater resistance to treatment. We 
have shown that this is also true in the general population. Women with MM can be 
offered different treatment strategies than other female migraineurs. The present thesis,
combined with previous studies, suggest that MM should be defined as a subtype of 
MO in the ICHD III.
8.2 Future questions 
Many questions remain unanswered. The role of the menstrual bleeding as such needs 
further exploration. Prospective studies of MM in relation to different types of 
hormonal contraception with and without inhibition of ovulation may represent models 
in order to study this. Another question is why only a subset of female migraineurs 
develops MM and why not all menstrual migraineurs report a constant association 
between migraine and menstruation from menarche to menopause. Genetic and 
experimental studies, together with epidemiological studies, might provide some 
answers.  The crucial point is that we all study the same group, which is only possible 
if the diagnostic criteria are used and interpreted in the same way. 
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10. Errata
Page/line Original text Revised text
18/2 Presented in table 2 Presented in table 1
21/20 “….prostaglandins 
have been proposed 
as a trigger migraine 
of MM”. 
“….prostaglandins have 
been proposed as a trigger 
of MM”. 
33/10 (Table 3) (Table 2)
35/1 Table 4 Table 3
37/8 Presented in Table 5 Presented in Table 4
38/7 Presented in Table 6 Presented in Table 5
43/20 (Appendix 2) (Appendix 3)
49/1 + 13 7.2.3 and 7.2.4 Removed from the text
50/1 7.2.5 Removed from the text
53/7 + 26 (Table 7) (Table 6)
55 Table 7 Table 6
73/question 1 Added the variable “1 day”
73/question 6 In 1 out of two 
menstruations
In 1 out of 2 menstruations
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11. Appendix
11.1 Appendix 1: The screening questionnaire 
Translated from the Norwegian original version
1 How many days did you 
experience headache during 
the preceding month?
Ƒ 0 days
Ƒ 1 day
Ƒ 2-6 days
Ƒ 7-14 days
Ƒ 15 days or more
2 How many days did you 
experience headache during 
the preceding year?
Ƒ 0 days
Ƒ 1-11 days
Ƒ 12-30 days
Ƒ 31-84 days
Ƒ 85-179 days
Ƒ 180 days or more
3 Have you ever had migraine? Ƒ Yes
Ƒ No
4 Have you had migraine during 
the preceding year?
Ƒ Yes
Ƒ No
5 Do you have migraine in 
relation to your menstruation?
Ƒ Yes
Ƒ No
6 How often do you have 
migraine in relation to your 
menstruation?
Ƒ Every time
Ƒ In 2 out of 3 menstruations
Ƒ In 1 out of 2 menstruations
Ƒ Seldom
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11.2 Appendix 2: Questions from the semi-structured interview 
                    Yes        No
1. Do you use contraception?
2. Type Amenorrhoea
Yes    No
a. Combined oral contraceptive pill (monophasic)
b. Combined oral contraceptive pill (multiphasic)
c. Transdermal patch
d. Combined contraceptive vaginal ring
e. Etonorgestrel implant
f. Progestin-only pill
g. Levonorgestrel intrauterine system
h. DMPA-injection
i. Copper intrauterine device
3. Did your migraine without aura change after initiation of current contraceptive 
method regarding
Less Unchanged More
Frequency
Better Unchanged Worse
Pain intensity
Shorter Unchanged Longer
Attack duration
4. Duration of current contraceptive treatment (months)
Translated from the Norwegian original version
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11.3 Appendix 3: The headache- and menstruation diary
ID number Date: / / / / / /
When did the headache start?                  Indicate nearest  hour:
Before headache started, was there                       vision:
there any disturbance of:           numbness/tingling in your skin:
   other disturbances:
Is the headache right sided:
left sided:
on both sides:
Is the headache Pulsating/throbbing:
tightening/pressuring:
How intense is the headache on a scale from 0-10
(0=no pain, 10=worst imaginable pain)
Does the headache change by routine  aggravation:
physical activity? unchanged:
improved:
Do you suffer from nausea during headache? no:
mild:
moderate:
severe:
Are you bothered by light during headache? no:
mild:
moderate:
                                                                           severe:
Are you bothered by sounds during headache? no:
mild:
moderate:
                                                                           severe:
When did the headache end? Indicate nearest  hour:
Menstruation (x)
Spotting (x)
Sick leave                                                                              yes:
                                                                                                no:
Did you take any medication? Please record name, dose and  
time taken  
Translated from the Norwegian original version
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